Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
Tata India Pharma & Healthcare Fund Direct Growth
+23.74%
3Y annualised
-0.19% 1D
NAV: 11 Jun '26
₹36.79
Min. for SIP
₹100
Fund size (AUM)
₹1,386.99 Cr
Expense ratio
0.96%
Rating
3
Return calculator
Monthly investment
₹5,000
| Over the past | Total investment | Would've become | Historic returns | Returns |
|---|---|---|---|---|
| 1 year | ₹60,000 | ₹62,551 | +4.25% | |
| 3 years | ₹1,80,000 | ₹2,16,015 | +20.01% | |
| 5 years | ₹3,00,000 | ₹4,51,330 | +50.44% | |
| 10 years | ₹6,00,000 | ₹15,32,799 | +155.47% |
Holdings (39)
| Name | Sector | Instruments | Assets |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 9.87% |
| Divi's Laboratories Ltd | Healthcare | Equity | 5.92% |
| Healthcare Global Enterprises Ltd | Healthcare | Equity | 5.45% |
| Abbott India Ltd | Healthcare | Equity | 5.37% |
| Max Healthcare Institute Ltd | Healthcare | Equity | 5.17% |
| Cipla Ltd | Healthcare | Equity | 5.07% |
| Rainbow Childrens Medicare Ltd | Healthcare | Equity | 4.23% |
| Apollo Hospitals Enterprise Ltd | Healthcare | Equity | 4.06% |
| Dr. Reddy's Laboratories Ltd | Healthcare | Equity | 3.73% |
| Mankind Pharma Ltd. | Healthcare | Equity | 3.73% |
| Fortis Healthcare Ltd | Healthcare | Equity | 3.55% |
| Bayer CropScience Ltd | Materials | Equity | 3.34% |
| Metropolis Healthcare Ltd | Healthcare | Equity | 3.07% |
| Lupin Ltd | Healthcare | Equity | 2.94% |
| Syngene International Ltd | Healthcare | Equity | 2.94% |
| Sai Life Sciences Ltd. | Healthcare | Equity | 2.63% |
| Dr. Lal Pathlabs Ltd | Healthcare | Equity | 2.60% |
| Alkem Laboratories Ltd | Healthcare | Equity | 2.49% |
| Glaxosmithkline Pharmaceuticals Ltd | Healthcare | Equity | 2.44% |
| Neuland Laboratories Ltd | Healthcare | Equity | 2.41% |
| JB Chemicals & Pharmaceuticals Ltd | Healthcare | Equity | 2.21% |
| Global Health Ltd | Healthcare | Equity | 2.16% |
| FDC Ltd | Healthcare | Equity | 1.94% |
| Ajanta Pharma Ltd | Healthcare | Equity | 1.90% |
| Vijaya Diagnostic Centre Ltd | Healthcare | Equity | 1.72% |
| Sanofi India Ltd | Healthcare | Equity | 1.68% |
| Procter & Gamble Health Ltd | Healthcare | Equity | 1.55% |
| Torrent Pharmaceuticals Ltd | Healthcare | Equity | 1.01% |
| CORONA Remedies Ltd. | Healthcare | Equity | 0.77% |
| Tata Chemicals Ltd | Materials | Equity | 0.72% |
| Aurobindo Pharma Ltd | Healthcare | Equity | 0.70% |
| PI Industries Ltd | Materials | Equity | 0.70% |
| HDFC Life Insurance Co Ltd | Financial | Equity | 0.67% |
| Sumitomo Chemical India Ltd | Materials | Equity | 0.43% |
| Jubilant Pharmova Ltd | Healthcare | Equity | 0.36% |
| Repo | Unspecified | Repo | 0.22% |
| Cash/Net Current Assets | Unspecified | Cash/Net Current Assets | 0.18% |
| Dr. Agarwal’S Health Care Ltd. | Healthcare | Equity | 0.07% |
| Ipca Laboratories Ltd | Healthcare | Equity | 0.00% |
See All
Minimum investments
Min. for 1st investment
₹5,000
Min. for 2nd investment
₹1,000
Min. for SIP
₹100
Returns and rankings
Annualised returns
Absolute returns
| Name | 3Y | 5Y | 10Y | All |
|---|---|---|---|---|
| Fund returns | +23.7% | +14.5% | +14.9% | +13.3% |
| Category average (Equity Sectoral) | +22.1% | +14.6% | +12.0% | -- |
| Rank (Equity Sectoral) | 5 | 4 | 2 | -- |
Exit load, stamp duty and tax
Exit load
Exit load of 0.25% if redeemed within 30 days.
Stamp duty on investment: 0.005% (from July 1st, 2020)
from July 1st 2020
Tax implication
If you redeem within one year, returns are taxed at 20%. If you redeem after one year, returns exceeding Rs 1.25 lakh in a financial year are taxed at 12.5%.
Check past data
Fund management
RSRajat SrivastavaSep 2024 - PresentView details
RS
Rajat Srivastava
Sep 2024 - Present
View details
About Tata India Pharma & Healthcare Fund Direct Growth
Tata India Pharma & Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by Tata Mutual Fund. This scheme was made available to investors on 30 Jun 1995. Rajat Srivastava is the Current Fund Manager of Tata India Pharma & Healthcare Fund Direct Growth fund. The fund currently has an Asset Under Management(AUM) of ₹2,25,507 Cr and the Latest NAV as of 11 Jun 2026 is ₹36.79.
The Tata India Pharma & Healthcare Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to ₹100. Minimum Lumpsum Investment is ₹5,000. Exit load of 0.25% if redeemed within 30 days.
;
Investment Objective
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund benchmarkBSE Healthcare Total Return Index
Fund house
Rank (total assets)#14 in India
Total AUM₹2,25,506.60 Cr
Date of Incorporation30 Jun 1995
Launch Date30 Jun 1995
Address9th Floor, Mafatlal Centre,Nariman Point, Mumbai 400021
Websitewww.camsonline.com
Address7th Floor, Tower II, Rayala Towers, 158, Anna Salai,